Sheppard MC - Search Results

1

Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.

Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM. Sherlock M, et al. Among authors: sheppard mc. J Clin Endocrinol Metab. 2009 Apr;94(4):1255-63. doi: 10.1210/jc.2008-1420. Epub 2009 Jan 21. J Clin Endocrinol Metab. 2009. PMID: 19158203

2

The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly.

Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM. Jenkins D, et al. Among authors: sheppard mc. Clin Endocrinol (Oxf). 1995 Nov;43(5):517-22. doi: 10.1111/j.1365-2265.1995.tb02913.x. Clin Endocrinol (Oxf). 1995. PMID: 8548933

3

Treatment options for acromegaly.

Sheppard MC, Stewart PM. Sheppard MC, et al. Metabolism. 1996 Aug;45(8 Suppl 1):63-4. doi: 10.1016/s0026-0495(96)90085-2. Metabolism. 1996. PMID: 8769385 Review.

4

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Davies PH, et al. Among authors: sheppard mc. Clin Endocrinol (Oxf). 1998 Mar;48(3):311-6. doi: 10.1046/j.1365-2265.1998.00389.x. Clin Endocrinol (Oxf). 1998. PMID: 9578821

5

Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).

Stewart PM, Stewart SE, Clark PM, Sheppard MC. Stewart PM, et al. Among authors: sheppard mc. Clin Endocrinol (Oxf). 1999 Mar;50(3):295-9. doi: 10.1046/j.1365-2265.1999.00660.x. Clin Endocrinol (Oxf). 1999. PMID: 10435053

6

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Ayuk J, et al. Among authors: sheppard mc. J Clin Endocrinol Metab. 2004 Apr;89(4):1613-7. doi: 10.1210/jc.2003-031584. J Clin Endocrinol Metab. 2004. PMID: 15070920

7

Evidence for the use of igf-I as a predictor of mortality in acromegaly is lacking.

Ayuk J, Sheppard MC, Clayton RN, Bates AS, Stewart PM. Ayuk J, et al. Among authors: sheppard mc. J Clin Endocrinol Metab. 2004 Nov;89(11):5867-8; author reply 5868. doi: 10.1210/jc.2004-1475. J Clin Endocrinol Metab. 2004. PMID: 15531556 No abstract available.

8

Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.

Sherlock M, Aragon Alonso A, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM. Sherlock M, et al. Among authors: sheppard mc. Clin Endocrinol (Oxf). 2009 Jul;71(1):74-81. doi: 10.1111/j.1365-2265.2008.03461.x. Epub 2008 Oct 26. Clin Endocrinol (Oxf). 2009. PMID: 19178529

9

ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly.

Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM. Sherlock M, et al. Among authors: sheppard mc. J Clin Endocrinol Metab. 2009 Nov;94(11):4216-23. doi: 10.1210/jc.2009-1097. Epub 2009 Oct 6. J Clin Endocrinol Metab. 2009. PMID: 19808848

10

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.

Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Stewart PM, et al. Among authors: sheppard mc. J Clin Endocrinol Metab. 1995 Nov;80(11):3267-72. doi: 10.1210/jcem.80.11.7593436. J Clin Endocrinol Metab. 1995. PMID: 7593436 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

279 results

Search Page

Filters